Video

ADHD Coaching During COVID-19

Author(s):

The role of many in psychiatry has changed during the COVID-19 pandemic.

The coronavirus disease 2019 (COVID-19) has changed the role of many across the spectrum of medicine, including psychiatrists.

Many of these clinicians must treat patients now dealing with enhanced feelings of stress, frustration, and self-concern, while also dealing with similar feelings for themselves.

This can be an issue, but the role of attention deficit/hyperactivity disorder (ADHD) coaches might become even more crucial.

In an interview with HCPLive®, Elizabeth Ahmann, Research Director of the Springer Institute and Micah Saviet, Director of the Springer Institute, discussed how the role of the ADHD coach may not have changed much during the ongoing pandemic, but specific of what ADHD individuals need has shifted.

Ahmann said in the past a common issue for individuals with ADHD was getting to work on time. However, because of the massive shift to a work from home setting across the board, some of the current issues include how to manage the stress and potential distractions in working from home.

There are also differing challenges in terms of socialization and physical activity than there was prior to the pandemic.

However, overall coaches still need to be cognizant of how ADHD can impact the daily life of the individual.

The researchers recently presented data from a focus group on what is needed to improve ADHD coaching during the American Professional Society of ADHD and Related Disorders (APSARD) 2021 Annual Conference.

Related Videos
Abdul Abdellatif, MD: More Gout Education Needed for Nephrologists
Violeta Popov, MD, PhD | Credit: ACG
Satish Rao, MD, PhD | Credit: ACG
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Jonathan Barratt, MD, PhD | Credit: IgA Nephropathy Foundation
Ladan Zand, MD: Evaluating Obinutuzumab in Primary FSGS and Further Research
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
© 2024 MJH Life Sciences

All rights reserved.